Neurocrine Biosciences will acquire Soleno Therapeutics for $2.9 billion in cash, driving Soleno shares up ~33% in pre-market trading. The transaction represents a meaningful M&A exit in the biotech sector and a sizeable cash premium for Soleno shareholders. Monitor regulatory approval risk and potential balance-sheet and pipeline integration implications for Neurocrine.
Neurocrine Biosciences will acquire Soleno Therapeutics for $2.9 billion in cash, driving Soleno shares up ~33% in pre-market trading. The transaction represents a meaningful M&A exit in the biotech sector and a sizeable cash premium for Soleno shareholders. Monitor regulatory approval risk and potential balance-sheet and pipeline integration implications for Neurocrine.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.75
Ticker Sentiment
